Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06471946
PHASE1/PHASE2

VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS

Sponsor: Navy General Hospital, Beijing

View on ClinicalTrials.gov

Summary

The goal of this phase 1/2 trial is to test the safety and efficacy of Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT in treating patients with higher-risk MDS.

Official title: Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT for Elderly Patients With Higher-risk Myelodysplastic Syndromes

Key Details

Gender

All

Age Range

70 Years - Any

Study Type

INTERVENTIONAL

Enrollment

54

Start Date

2024-10-01

Completion Date

2030-09-01

Last Updated

2024-10-01

Healthy Volunteers

No

Interventions

DRUG

Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT

Patients were treated by VA Conditioning Regimen Allo-HSCT: Venetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-14; Azacytidine 75 mg/m2 subcutaneous injection qd d1-7, donor stem cells infused from d9

Locations (1)

Navy General Hospital

Beijing, Beijing Municipality, China